		START	Form				
tep 2. Fax this form and c or to Otezla Suppo	ll fields on this form (to preven copies of both sides of insuran ortPlus™. FAX# nore information, please visit o	nt delays in processing). ce and pharmacy benefit car Preferro	rds to the specialty pharma ed SP NAME			ezla PORTPLUS	
		Section 1: Patie	nt Information				
Name (First, MI, Last)		Last 4 digi	ts of SS # Da	ate of birth / /	□ Mi	ale 🗌 Femal	
	No P.O. Box						
	Pre						
*By providing my phone numb condition or treatment. Amge	er, I consent to Amgen calling and text en may use automatic dialing machines not required to provide this consent a	ing me at the phone number(s) I hav or artificial or prerecorded messag s a condition of purchasing any good	ve provided with promotional com es to contact me and may leave a ds or services. Reply STOP to cance	munications relating to Amgen pr voicemail or SMS/text message (st	roducts and servio	ces and/or my	
	od 🔲 Dharmary hopofit card a	Section 2: Insurar		adary incurance			
	Insurance card attached Pharmacy benefit card attach		cy # Group #				
				PBM phone			
					IN (if applicable)		
_			aroup ID	КХ ВІМ (ІГ арріїсаріе)			
I understand that co-pay assista	e to enroll in the Otezla Co-pay nce is only available for commercially insu o the attached HIPAA Authoriza	ired patients and does not apply if I ha			gram.		
Patient/patient repres	entative signature			Date (MM/DD/Y	'YYY)/_	/	
(If signed by patient representa	tive, please explain authority to act on be	ehalf of the patient)					
	Section 3: Clini	cal Information (TO BE CC	OMPLETED BY HEALTHCA	RE PROVIDER)			
PRIMARY DIAGNOSIS/	L40.50 (Arthropathic psoria	·		aris) %BSA Affected			
ICD-10-CM Code:	L40.51 (Distal interphalange						
	L40.52 (Psoriatic arthritis m	utilans)		L40.9 (Psoriasis, unspecified) %BSA Affected			
	L40.53 (Psoriatic spondylitis	•	🗌 M35.2 (Behçet's Dis	ease)			
	L40.59 (Other psoriatic arth						
· · · •	PsO ONLY): Hands A	rms 🗌 Nails 🗌 Trun	k 🗌 Feet 🗌 Legs	Scalp Groin	Other_		
PREVIOUS/CURRENT TR Medication Du	EATMENT: Jration/Reason for D/C	Medication		Duration/Reason fo	or D/C		
Methotrexate	<u>aracion/recision rot byc</u>						
Cyclosporine							
Sulfasalazine		Other					
Acitretin							
PUVA or UV		ADDITIONAL MEDICA	AL JUSTIFICATION				
Colchicine							
Sect	ion 4: Prescription for OTE2	LA <sup>®</sup> (apremilast) FOR OR	AL USE (TO BE COMPLET	ED BY HEALTHCARE PRC	VIDER)		
STEP 1: SELECT TITRA	TION	2 STEP 2: SELECT MAINTE	NANCE DOSE	3 STEP 3: SELECT BRID	GE (IF APPLICA	BLE)†	
Starter Pack (Titration) Rx for Otezla		Maintenance Rx—30 mg c	Maintenance Rx—30 mg of Otezla		Bridge Rx—30 mg of Otezla		
4-WEEK STARTER PACK* x28 days, 55 tablets, 0 refills		🗌 x30 days 🔲 x90 days		TWICE DAILY			
		TWICE DAILY		x14 days, 28 tablets, 12 refills			
PRESCRIBER PROVIDED PATIENT WITH 2-WEEK STARTER PACK SAMPLE x14 days, 27 tablets, 0 refills Date provided / /		ONCE DAILY renal dose 30 mg (For patients with severe renal impairment)		ONCE DAILY renal dose 30 mg x28 days, 28 tablets, 6 refills			
		Refills: 🗌 11 🗌 Other	Refills: 🔲 11 🗌 Other amount (enter #)		<sup>1</sup> Bridge Rx is at no cost for eligible commercially insured, on-labe diagnosed patients only, and is not contingent on purchase requirements of any kind. Bridge Rx is not available to enrollees		
Additional information		Special instructions		in Medicare, Medicaid, and ol	ther federal and st	ate programs	
				intended to support continua is a delay in determining whe	ation of prescribed ther commercial p	l therapy if there prescription	
a titration sample during the	ly for patients who did not receive ir office visit. The specialty pharmacy phone prior to each shipment.		c		coverage is available. In Step 1, please indicate if you provided the patient with the 2-week Starter Pack sample, or if the 4-week Starter Pack needs to be dispensed.		
	Section 5: Presc	riber Information (TO BE C	COMPLETED BY <u>HEALTHC</u>	ARE PROVIDER)			
Name (First , Last)			Facility name				
	Fax	NPI # DE	A # Offic				
		Best time to contact: 🗌 M	orning 🗌 Afternoon				
patient's medical treatment.	ATION* By signing this START Form I I authorize the release of medical and/ a-dispensing pharmacies) to use and di	certify that I have prescribed Otezla or other patient information relating	(apremilast) based on my profess g to Otezla therapy to agents and s	ervice providers of Amgen (includ	ing but not limite	d to Covance	
Supervising physician	signature and date (where re						
	able. *If required by applicable law, pleas			0	/	/	
Signature stamps not accept	and a negoried by applicable law, pleas	ה פנימנה נסקובי סרמו קרפינדוףנוסדא סד	onneiar state prescription norms.		020 Amgen Inc. Al 20 US-OTZ-20-060		

# **Patient Authorization to Share Health Information**



Please present this Authorization to the patient/patient representative and obtain the required signature.

#### Uses and Disclosure of Personal Information

I authorize Amgen and its contractors and business partners ("Amgen") to use and/or disclose my personal information, *including my personal health information*, only for the following purposes:

- To operate, administer, enroll me in, and/or continue my participation in Amgen's Otezla SupportPlus<sup>™</sup> program or any other Amgen-affiliated patient support services and activities related to my condition or treatment (for example, co-pay card programs, reimbursement assistance programs, drug coverage verification, nurse educator services, adherence program and disease management support);
- To contact, with my permission, my doctor and the rest of my health care team and share with them my health information that may be useful for my care;
- To provide me with informational and promotional materials relating to Amgen products and services, and/or my condition or treatment; and/or
- To improve, develop, and evaluate products, services, materials and programs related to my condition or treatment.

In order for Amgen to provide me with the services and/or programs described above, Amgen needs to collect and use my personal information, including *my personal health information*. I understand that *my personal health information* may include any information, in electronic or physical form, in the possession of or derived from a health care provider, health care plan, pharmacy, pharmaceutical company, laboratory and/or their contractor ("Health Care Provider"). This may include select information from or about my medical history and general health, my health care plan benefits, payment limits or restrictions covered by my health care plan policy, and/or my adherence to my treatment.

I authorize my Health Care Providers to disclose *my personal health information* to Amgen, and between themselves, as necessary, but only for the purposes stated above in this Authorization. I understand that certain of my Health Care Providers (such as pharmacies and specialty pharmacies) may receive remuneration from Amgen in exchange for disclosing *my personal health information* and/or for using my information to contact me with communications about Amgen products which have been prescribed to me (for example medication reminder programs) and other patient support services.

#### Expiration, Right to Obtain a Copy and Right to Cancel

I understand that by signing this form, I authorize my Health Care Providers or others who might hold my health information to only release it to Amgen employees, as well as to its contractors and business partners, who are performing the services set forth in this Authorization. I also understand I am authorizing my personal information, including *my personal health information*, to be used for the purposes described above. I understand and agree that by signing below, I am authorizing those who rely on this Authorization to release my personal health information for the earlier of five (5) years or until my participation in the program ends through my cancellation, unless a shorter time period is required by state law.

I understand that I can obtain a copy of this Authorization or cancel this Authorization at any time by calling Amgen at 1-844-468-3952 or by writing to PO BOX 13185, La Jolla, California, 92039. If I cancel my consent, I will no longer qualify for the services described. I also understand that if a Health Care Provider is disclosing my personal health information to Amgen on an authorized on-going basis, my cancellation with Amgen will be effective with respect to any such Health Care Providers as soon as they receive notice of my cancellation.

#### No Effect on Treatment

I understand I do not have to sign this Authorization and that my enrollment in any of the services and/or programs described above is entirely voluntary. I understand that Amgen, as well as Health Care Providers, cannot require me, as a condition of having access to medications, prescription drugs, treatment or other care, to sign this Authorization. Federal Law (including HIPAA) requires a signed authorization in order for Amgen to collect this information from my Health Care Providers. I understand I cannot participate in the listed services and/or programs without signing this Authorization or an equivalent authorization with my Health Care Providers.

#### **Information Received from Health Care Providers**

I understand that once my personal health information has been disclosed to Amgen, federal privacy laws may no longer apply and protect it from further disclosure. Amgen agrees, however, to protect my personal health information by only using and disclosing it as stated in the Authorization or as otherwise allowed or required by law.

#### Authorization to Contact

I understand and consent to Amgen contacting me using the contact information provided in this form to enroll me in, operate, and administer Amgen patient support services and/or programs as described above other than promotional communications by telephone or SMS/text (which I can separately opt-in below). I understand that the operation and administration of certain of these services and/or programs may require that Amgen contact me by telephone or SMS/text.




# Filling an Otezla prescription

# PRESCRIBE

Prescribe Otezla® (apremilast) 30-mg tablets for an appropriate patient

### PREPARE



# Otezla SupportPlus™ can help with access

This support network includes resources for you and your patients.

### **REIMBURSEMENT SUPPORT**

- Benefits investigation and PA assistance
- Assessment of patient eligibility for Medicare coverage
- Appeals support for coverage denials
- Specialty pharmacy triage and coordination
- Status updates on prescription fulfillment

# PATIENT SUPPORT

- 24/7 access to specially trained nurses
- \$0 co-pay\* enrollment and follow-up
- Live insurance support
- Updates on prescription status
- Shipment of free bridge to maintenance supply during potential reimbursement delays for commercially insured patients

# **Financial assistance options**

#### **COMMERCIALLY INSURED**

# Otezla Savings Program

Eligibility requirements:

- Commercially insured (no Medicare or Medicaid)
- Patient must be a US resident

Be sure to remind your patients that they may be eligible for a \$0 co-pay,\* and to ask their specialty pharmacy about financial offers that may be available to them.

### MEDICARE & MEDICAID

Independent Co-pay Foundations & State Programs

Eligibility requirements:

(may vary by foundation):

- Each fund has its own enrollment process
- Patients can receive funding as needed

### **UNINSURED OR UNDERINSURED**

#### Patient Assistance Program

Eligibility requirements:

- On-label diagnosis
- For uninsured or underinsured patients
- Patient must be a US resident
- Patient must meet financial requirements

\*Certain restrictions apply. This offer is not valid for persons eligible for reimbursement of this product, in whole or in part, under Medicaid, Medicare, or similar state or federal programs. Offer void where prohibited by law.

# **Questions? Need more information?**

#### Call Otezla SupportPlus™ at 1-844-4OTEZLA (1-844-468-3952)

8 AM – 8 PM ET, Monday – Friday



# The right information speeds the process

Any incorrect or missing information on the START Form can delay the approval process.

# Did you remember to

Fax completed and signed Otezla START Form to Otezla SupportPlus™ (Patient signature is not required during a telemedicine visit.)

Note the patient's titration start date if you provided the Starter Pack directly to your patient

Check "Bridge Rx – 30 mg of Otezla® (apremilast)" in section 4 of the START Form

# Additional helpful tips

Indicate permission to leave a message with patient

Include copies of both sides of the patient's
 (1) prescription benefit card and (2) medical benefit card

Fax any clinical notes helpful in establishing diagnosis to the SP or OSP

- Need a PA form? One can be provided by the patient's insurance company
- If you have questions about filling out the START Form, Otezla SupportPlus<sup>™</sup> is here to help you every step of the way. Just call us at 1-844-4OTEZLA (1-844-468-3952) 8 AM 8 PM ET, Monday Friday



# How to start on Otezla

# Starting with in-office sample:

#### Otezla® (apremilast) 30 mg Starter Pack

 2 weeks of medication, including 5 days of titration doses

# Starting with the specialty pharmacy:

#### Otezla 30 mg 28-Day Pack

 Includes 5 days of titration doses and additional maintenance doses if Starter Pack is not provided in office





\*To receive a free Bridge supply of Otezla, commercially insured patients must have an on-label diagnosis and be denied or waiting for coverage. If an in-office Starter Pack (Titration) is not available, please check both the 4-week Starter Pack and Bridge Rx boxes.

# **INDICATIONS**

Otezla<sup>®</sup> (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease.

# **IMPORTANT SAFETY INFORMATION**

## **Contraindications**

• Otezla<sup>®</sup> (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

### Warnings and Precautions

- Diarrhea, Nausea, and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
- Depression: Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
  - <u>Psoriasis</u>: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide
  - Psoriatic Arthritis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo-treated patients. Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo-treated patients who received placebo committed suicide compared to none on Otezla
  - <u>Behçet's Disease</u>: Treatment with Otezla is associated with an increase in depression. During the clinical trial, 1% (1/104) reported depression or depressed mood compared to 1% (1/103) treated with placebo. No instances of suicidal ideation or behavior were reported in patients treated with Otezla or treated with placebo



### Indications and Important Safety Information (cont'd)

- Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
  - <u>Psoriasis</u>: Body weight loss of 5-10% occurred in 12% (96/784) of patients treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo
  - <u>Psoriatic Arthritis</u>: Body weight loss of 5-10% was reported in 10% (49/497) of patients taking Otezla and in 3.3% (16/495) of patients taking placebo
  - <u>Behçet's Disease</u>: Body weight loss of >5% was reported in 4.9% (5/103) of patients taking Otezla and in 3.9% (4/102) of patients taking placebo
- Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

### **Adverse Reactions**

- <u>Psoriasis</u>: Adverse reactions reported in ≥5% of patients were (Otezla%, placebo%): diarrhea (17, 6), nausea (17, 7), upper respiratory tract infection (9, 6), tension headache (8, 4), and headache (6, 4)
- <u>Psoriatic Arthritis</u>: Adverse reactions reported in at least 2% of patients taking Otezla, that occurred at a frequency at least 1% higher than that observed in patients taking placebo, for up to 16 weeks (after the initial 5-day titration), were (Otezla%, placebo%): diarrhea (7.7, 1.6); nausea (8.9, 3.1); headache (5.9, 2.2); upper respiratory tract infection (3.9, 1.8); vomiting (3.2, 0.4); nasopharyngitis (2.6, 1.6); upper abdominal pain (2.0, 0.2)
- <u>Behçet's Disease</u>: Adverse reactions reported in ≥5% of patients taking Otezla, that occurred at a frequency at least 1% higher than that observed in patients taking placebo, for up to 12 weeks, were (Otezla%, placebo%): diarrhea (41.3, 20.4); nausea (19.2, 10.7); headache (14.4, 10.7); upper respiratory tract infection (11.5, 4.9); upper abdominal pain (8.7, 1.9); vomiting (8.7, 1.9); back pain (7.7, 5.8); viral upper respiratory tract infection (6.7, 4.9); arthralgia (5.8, 2.9)

### Use in Specific Populations

- Pregnancy: Otezla has not been studied in pregnant women. Advise pregnant women of the potential risk of fetal loss. Consider pregnancy planning and prevention for females of reproductive potential. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Otezla during pregnancy. Information about the registry can be obtained by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/otezla/
- Lactation: There are no data on the presence of apremilast or its metabolites in human milk, the effects of apremilast on the breastfed infant, or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Otezla and any potential adverse effects on the breastfed child from Otezla or from the underlying maternal condition
- Renal Impairment: Otezla dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information

# Please <u>click here</u> for Full Prescribing Information.



